Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341012 · ClinicalTrials.gov registry record
Breath Analysis Based Disease Biomarkers
A clinical trial of COVID-19 and Liver Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- 46
- Enrollment target
- 1
- Study location
NCT04341012: Completed study of COVID-19 and Liver Cancer, sponsored by Mayo Clinic.
NCT04341012 is a study of COVID-19 and Liver Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 46 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04341012, a study of COVID-19 and Liver Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
Primary Outcome
Detection of profiles of volatile organic compounds present in exhaled breath. The values in the table represent the number of participants from whom a volatile organic compound profile was able to be detected.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Collection of breath sample
Study Locations (1)
Florida
- Mayo Clinic Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-09-10 |
| Est. Completion | 2021-09-03 |
What the finished NCT04341012 record still lists
NCT04341012 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Collection of breath sample is the first listed.
NCT04341012 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04341012 about?
NCT04341012 is a clinical study titled "Breath Analysis Based Disease Biomarkers". The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
What is the current status of trial NCT04341012?
This trial is currently completed. The enrollment target is 46 participants. The study started on 2019-09-10. Estimated completion is 2021-09-03.
What conditions does trial NCT04341012 study?
This clinical trial studies the following conditions: COVID-19, Liver Cancer, Liver Diseases.
What interventions are being tested in trial NCT04341012?
The interventions under investigation include: Collection of breath sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04341012?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04341012 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04341012's enrollment target sits among peer trials
46 253rd of 298 higher than 46 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI